teaser
IS Pharma is pleased to announce that from April 1st 2011 episil®, an oral spray indicated for local treatment of pain associated with oral mucositis, will be listed on the NHS Drug Tariff for England and Wales.
This will make prescribing and patient access to treatment easier and more convenient for healthcare professionals.
episil® uses a patented, lipid-based technology that spreads on the intra-oral mucosal surfaces and transforms in to a strongly bioadhesive FluidCrystal film that protects the oral cavity.
episil® has been shown to provide rapid and prolonged pain reduction (for up to eight hours) in patients with oral mucositis. (Tiberg F, E et al. Data on file)
For patients, episil® provides added convenience as it is administered from an easy, ready to use multi-dose device. There is no need to gargle or rinse and it has a simple dosage regime of 1-3 sprays, 2-3 times per day.
IS Pharma is confident that listing on the Tariff will ensure more patients suffering from oral mucositis will benefit from episil®
